WHO-Led Draft COVID-19 Drug Scheme Prioritizes Monoclonal Antibodies, Steroids, Eschews Remdesivir; Media Outlets, Medical Journal Report On Other Therapeutic Research

Reuters: Exclusive: WHO-led COVID drug scheme doubles down on antibodies, steroids and shuns remdesivir
“A World Health Organization-led scheme to supply COVID-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead’s remdesivir therapy, an internal document shows. The Oct. 30 WHO draft document seen by Reuters says priorities are to secure monoclonal antibodies in a tight market and to boost distribution of cheap steroid dexamethasone, of which it has already booked nearly 3 million courses of treatment for poorer countries…” (Guarascio et al., 11/5).

Financial Times: Regeneron looks to target most in-need patients for Covid drug (Kuchler, 11/5).

NEJM: Remdesivir for the Treatment of Covid-19 — Final Report (Beigel et al., 11/5).

New York Times: Nasal Spray Prevents Covid Infection in Ferrets, Study Finds (McNeil, 11/5).

The Telegraph: Hydroxychloroquine does not prevent death when taken before exposure to Covid, study finds (Newey, 11/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.